Suppr超能文献

解决争议:在估计肾功能时使用种族的未来。

Resolving the Debate: The Future of Using Race in Estimating Kidney Function.

机构信息

Nephrology Section, San Francisco VA Medical Center, San Francisco, CA; Department of Medicine, University of California, San Francisco, San Francisco, CA.

Department of Medicine, Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, San Francisco, CA; Department of Medicine, University of California, San Francisco, San Francisco, CA.

出版信息

Adv Chronic Kidney Dis. 2022 Jan;29(1):5-16. doi: 10.1053/j.ackd.2022.02.001.

Abstract

Racial and social unrest witnessed during 2020 ignited a national conversation about the appropriateness of the use of race in health care algorithms and in the estimation of kidney function in particular. The growing concerns over the use of race in kidney function-estimating equations prompted the National Kidney Foundation (NKF) and American Society of Nephrology to launch an effort for change by establishing a task force on reassessing the use of race in diagnosing kidney disease. After nearly a year examining the evidence and obtaining testimony from experts and stakeholders, the task force recommended the immediate implementation of the 2020 Chronic Kidney Disease-Epidemiology creatinine equation refit without race in all US laboratories; increased routine use of cystatin C for confirmation of estimated glomerular filtration rate in clinical decision-making and a call for research on glomerular filtration rate estimation with new endogenous filtration markers and on addressing disparities in health and health care. The NKF and American Society of Nephrology strongly encouraged rapid adoption of these new recommendations. Leadership efforts of the NKF have begun to lay the foundation for national implementation through laboratory engagement, clinician awareness, and patient education.

摘要

2020 年,种族和社会动荡引发了一场全国性的讨论,探讨在医疗保健算法中以及特别是在估计肾功能时使用种族的适当性。人们对在肾功能估计方程中使用种族的担忧日益增加,促使美国国家肾脏基金会(NKF)和美国肾脏病学会发起了一项变革努力,成立了一个专门评估在诊断肾脏疾病时使用种族问题的工作组。经过近一年的审查证据,并从专家和利益相关者那里获得证词,工作组建议立即在所有美国实验室实施 2020 年慢性肾脏病-肌氨酸酐方程的重新评估,不考虑种族因素;增加胱抑素 C 的常规使用,以在临床决策中确认估算肾小球滤过率,并呼吁研究使用新的内源性滤过标志物进行肾小球滤过率估计以及解决健康和医疗保健方面的差异。NKF 和美国肾脏病学会强烈鼓励迅速采用这些新建议。NKF 的领导层已经开始通过实验室参与、临床医生意识和患者教育为全国实施奠定基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验